Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice

Fung, 1990, Overview of FK506 in transplantation, Clin Transpl, 115 Jordan, 2008, C. sinensis ablates allograft vasculopathy when used as an adjuvant therapy with cyclosporin A, Transpl Immunol, 19, 159, 10.1016/j.trim.2008.05.010 Peddi, 1998, Use of tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation, Clin Transplant, 12, 401 Onsager, 1999, Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients, J Heart Lung Transplant, 18, 448, 10.1016/S1053-2498(99)00016-9 Haeryfar, 2008, Prolongation of cardiac allograft survival by rapamycin and the invariant natural killer T cell glycolipid agonist OCH, Transplantation, 86, 460, 10.1097/TP.0b013e3181806b72 Condé, 2008, Roxithromycin reduces cyclosporine-induced gingival hyperplasia in renal transplant patients, Transplant Proc., 40, 1435, 10.1016/j.transproceed.2008.04.012 Mueller, 1994, Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506, Transplantation, 58, 155, 10.1097/00007890-199405820-00006 Kamar, 2005, Diabetes mellitus after kidney transplantation: a French multicentre observational study, Nephrol Dial Transplant, 22, 1986, 10.1093/ndt/gfm011 Molinari, 2005, Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases, Am J Transplant, 5, 2799, 10.1111/j.1600-6143.2005.01082.x Brinkmann, 2004, FTY720: mechanism of action and potential benefit in organ transplantation, Yonsei Med J, 45, 991, 10.3349/ymj.2004.45.6.991 Chiba, 2005, FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptor, Pharmacol Ther, 108, 308, 10.1016/j.pharmthera.2005.05.002 Schuurman, 2002, Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD, Transplantation, 74, 951, 10.1097/00007890-200210150-00009 Baumruker, 2007, FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis, Expert Opin Investig Drugs, 16, 283, 10.1517/13543784.16.3.283 Matsuura, 1991, Simplified mouse cervical heart transplantation using a cuff technique, Transplantation, 51, 896, 10.1097/00007890-199104000-00031 Billingham, 1990, A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation, J Heart Transplant, 9, 587 Aneja, 2004, Epigallocatechin, a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats, Mol Med, 10, 55, 10.2119/2004-00032.Aneja Almawi, 2001, Inhibition of cytokine production and cytokine-stimulated T-cell activation by FK506 (tacrolimus), Cell Transplant, 10, 615, 10.3727/000000001783986387 Lafferty, 1984, Immunology of graft rejection, Transplant Proc, 16, 927 Krieger, 1996, CD4+ but not CD8+ cells are essential for allorejection, J Exp Med, 184, 2013, 10.1084/jem.184.5.2013 Pietra, 2000, CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II, J Clin Invest, 106, 1003, 10.1172/JCI10467 Morikawa, 1994, Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro, Clin Exp Immunol, 95, 514, 10.1111/j.1365-2249.1994.tb07028.x Yoshimura, 1989, Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2, Transplantation, 47, 356, 10.1097/00007890-198902000-00035 Banerji, 1991, The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1, Mol Cell Biol, 11, 4074, 10.1128/MCB.11.8.4074 Vu, 1997, Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat, Transplantation, 64, 1853, 10.1097/00007890-199712270-00039 Qi, 1999, Malononitrilamides and tacrolimus additively prevent acute rejection in rat cardiac allografts, Transpl Immunol, 7, 169, 10.1016/S0966-3274(99)80036-7 Shirouzu, 2004, Inhibition of acute rejection after skin or cardiac transplantation by administration of donor antigens in the rat, Surg Today, 34, 341, 10.1007/s00595-003-2701-5 Deuse, 2007, Is the malononitrilamide FK778 better for the prevention of acute or chronic rejection?, Transplant Proc, 39, 569, 10.1016/j.transproceed.2006.12.020 Qi, 2007, Effect of baohuoside-1 aglycone and tacrolimus monotherapy and combination therapy on prevention of acute heart allograft rejection in the rat, Microsurgery., 27, 268, 10.1002/micr.20353 Deuse, 2008, Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection, Transplantation, 85, 885, 10.1097/TP.0b013e318166acc4 Roncarolo, 2001, Type 1T regulatory cells, Immunol. Rev., 182, 68, 10.1034/j.1600-065X.2001.1820105.x